Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Wierda on the ASCEND Trial and BTK Inhibitor-Based Therapies in CLL

October 25th 2019

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Ublituximab Plus Ibrutinib Improves PFS in Relapsed/Refractory High-Risk CLL

October 25th 2019

The combination of ublituximab and ibrutinib improved progression-free survival, as determined by an Independent Review Committee, compared with ibrutinib alone in patients with relapsed/refractory high-risk chronic lymphocytic leukemia.

CLL Treatment Moves Toward Combo Approaches and CAR T-Cell Therapy

October 24th 2019

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

Dr. Smith on Frontline Treatment Considerations in CLL

October 24th 2019

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL/SLL

October 23rd 2019

Tanya Siddiqi, MD, discusses the rationale for the phase I/II TRANSCEND CLL 004 trial investigating the use of the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Mato on Immunotherapy Options in CLL

October 22nd 2019

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL

October 21st 2019

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Rituximab Sets the Pace in Changing Lymphoma Landscape

October 18th 2019

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

Dr. Smith on Using Venetoclax Versus Ibrutinib in CLL

October 17th 2019

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Gerson on Targeted Therapy Versus Chemotherapy in CLL

October 16th 2019

James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.

Dr. Mato on Utilizing CAR T Cells in CLL

October 15th 2019

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

Novel Agents, Combos Transforming Treatment in MCL and CLL

October 14th 2019

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon.

Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLL

October 8th 2019

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

Amid Explosion of Targeted Agents, FCR Retains a Role in CLL Paradigm

October 7th 2019

Mitchell R. Smith, MD, PhD, discusses the use of chemotherapy versus targeted therapy in patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Dr. Eradat Discusses Data With Acalabrutinib in CLL

October 5th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Smith on Utilizing Lenalidomide in CLL

October 4th 2019

Mitchell R. Smith, MD, PhD, discusses the potential advantage of lenalidomide in chronic lymphocytic leukemia.

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

October 4th 2019

James N. Gerson, MD, discusses the phase III CLL14 trial evaluating the combination of venetoclax and obinutuzumab versus chlorambucil and obinutuzumab as frontline therapy in chronic lymphocytic leukemia.

Dr. Eradat on the CAPTIVATE Trial in CLL

September 24th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unprecedented aspects of the phase II CAPTIVATE trial in chronic lymphocytic leukemia (CLL).

Dr. Smith on Ibrutinib-Based Therapies in CLL

September 23rd 2019

Mitchell R. Smith, MD, PhD, discusses two randomized phase III trials investigating the benefit of ibrutinib-based therapies in patients with chronic lymphocytic leukemia.

Dr. Eradat on the Unmet Needs in CLL

September 19th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unmet needs in chronic lymphocytic leukemia.